CHICAGO, Nov. 15, 2012 /PRNewswire/ -- Positron
Corporation (OTCBB:POSC), a nuclear medicine healthcare company,
announced today the appointment of Charles
Conroy as Chief Operating Officer.
Conroy's background includes extensive experience in corporate
& product strategy, partner & alliance management,
licensing, acquisitions, divestitures and portfolio management.
During his career, Conroy has led highly successful global business
development, marketing, and operations initiatives for companies
including Covidien, Eli Lilly, and Amerinet. Conroy
earned a Bachelor of Science in Pharmacy from Purdue University and a Master of Business
Administration from the University of
Michigan.
As COO, Conroy will define and implement strategies focused on
accelerating growth across the company's product portfolio.
Conroy joins Positron's clinical and technical executive
team, consisting of: Joseph Oliverio
(PET), Jason Kitten
(Radiopharmaceutical/Radioisotope Production) and Scott Stiffler (Pharmaceutical
Automation/Product Development). Conroy will also lead the
Company's sales and marketing initiatives; focusing on revenue
generation, enhancing Positron's industry position and brand
recognition as a leader in nuclear medicine.
Conroy commented, "I am very excited to be joining the Positron
team. As the only company with a full nuclear cardiology
solution, Positron is well positioned to take a leadership role in
the nuclear medicine industry. The caliber of the team and the
company's reputation coupled with its strong sense of purpose make
this a tremendous opportunity."
"Chuck's leadership, expertise and background of implementing an
integrated global sales and marketing plan adds tremendous value in
executing Positron's objectives," stated Patrick G. Rooney, Chief Executive Officer of
Positron. "Chuck's approach and track record will greatly
complement the knowledge and direction provided by each member of
our executive team in executing our vertically integrated solution
strategy. We are pleased with the addition of Chuck Conroy as our COO and I expect him to have
a significant impact in all aspects of our business. We have
developed a business model and team to deliver results."
About Positron: Positron Corporation is a nuclear medicine
healthcare company vertically integrating all the segments of
nuclear cardiology; providing an end-to-end solution for cardiac
PET. Through proprietary PET imaging systems,
radiopharmaceuticals and radioisotopes solutions, Positron enables
healthcare providers to more accurately diagnose disease and
improve patient outcomes, while practicing cost effective medicine.
Positron's unique products, market position and approach in
securing the supply chain are substantial advantages, further
accelerating the adoption of cardiac PET and growth of nuclear
cardiology. Positron is redefining the industry. More
information about Positron is available at www.positron.com.
Forward Looking Statements: Statements in this document
contain certain forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, as amended. These statements are
based on many assumptions and estimates and are not guarantees of
future performance. These statements may involve known and unknown
risks, uncertainties and other factors which may cause the actual
results, performance or achievements of Positron Corporation to be
materially different from future results, performance or
achievements expressed or implied by such forward-looking
statements. Positron assumes no obligation to publicly update or
revise these forward-looking statements for any reason, or to
update the reasons actual results could differ materially from
those anticipated in these forward-looking statements, even if new
information becomes available in the future. Our actual
results may differ materially from the results anticipated in these
forward-looking statements due to a variety of factors, including,
without limitation those set forth as "Risk Factors" in our filings
with the Securities and Exchange Commission.
SOURCE Positron Corporation